NEUP — Neuphoria Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $9.62m
- -$4.00m
- $15.65m
- 37
- 67
- 13
- 32
Annual income statement for Neuphoria Therapeutics, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | R2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | 10-K | 10-K | 10-K |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.191 | 0 | 0 | 15.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.34 | 16.3 | 22.6 | 17.9 | 16.8 |
| Operating Profit | -6.34 | -16.1 | -22.6 | -17.9 | -1.13 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.63 | -15.9 | -21.5 | -15.6 | -0.838 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.49 | -15.8 | -21.4 | -15.5 | -0.37 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -6.49 | -15.8 | -21.4 | -15.5 | -0.37 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.49 | -15.8 | -21.4 | -15.5 | -0.37 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.101 | -0.14 | -0.172 | -0.103 | -0.228 |